Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., et al
Although our study shows that federal policy change can help increase access to GLP-1s for heart disease, we still have a long way to go to ensure that patients can access and afford these medications as their clinical indications keep expanding, said first author Christopher Scannell, a nonresident scholar at the USC Schaeffer Institute and senior research associate at the USC Mann School of Pharmacy and Pharmaceutical Sciences
Providers can discuss options you may not have considered, including split dosing protocols, combination approaches involving metformin or phentermine as adjuncts, dose timing optimization, or even switching to a medication with a longer half-life that provides more consistent weekly coverage
Clinical trials provide free medication but involve 12-18 month commitments
This seemingly small change has a profound impact on the drug's pharmacokinetics: From Bench to Clinic: The Journey of Ozempic The development of semaglutide involved extensive preclinical studies, likely including research in animal models such as mice and rats